GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biostar Pharmaceuticals Inc (OTCPK:BSPM) » Definitions » Piotroski F-Score

Biostar Pharmaceuticals (Biostar Pharmaceuticals) Piotroski F-Score : 0 (As of Apr. 25, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Biostar Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biostar Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Biostar Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Biostar Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Biostar Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biostar Pharmaceuticals Piotroski F-Score Chart

Biostar Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 7.00 6.00 3.00 4.00

Biostar Pharmaceuticals Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 4.00 5.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep17) TTM:Last Year (Sep16) TTM:
Net Income was 3.388 + -1.014 + -1.314 + -0.125 = $0.94 Mil.
Cash Flow from Operations was 4.002 + 0.321 + 4.266 + -0.001 = $8.59 Mil.
Revenue was 0.318 + 0 + 0 + 0 = $0.32 Mil.
Gross Profit was -0.037 + 0 + 0 + 0 = $-0.04 Mil.
Average Total Assets from the begining of this year (Sep16)
to the end of this year (Sep17) was
(40.559 + 42.502 + 41.493 + 40.777 + 41.427) / 5 = $41.3516 Mil.
Total Assets at the begining of this year (Sep16) was $40.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.00 Mil.
Total Current Liabilities was $5.28 Mil.
Net Income was -23.205 + -0.62 + -6.902 + -1.564 = $-32.29 Mil.

Revenue was 1.838 + 0.802 + 0.62 + 0.645 = $3.91 Mil.
Gross Profit was 0.768 + 0.345 + 0.299 + 0.308 = $1.72 Mil.
Average Total Assets from the begining of last year (Sep15)
to the end of last year (Sep16) was
(78.468 + 51.364 + 50.375 + 42.056 + 40.559) / 5 = $52.5644 Mil.
Total Assets at the begining of last year (Sep15) was $78.47 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $7.29 Mil.
Total Current Liabilities was $6.53 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biostar Pharmaceuticals's current Net Income (TTM) was 0.94. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biostar Pharmaceuticals's current Cash Flow from Operations (TTM) was 8.59. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep16)
=0.935/40.559
=0.02305284

ROA (Last Year)=Net Income/Total Assets (Sep15)
=-32.291/78.468
=-0.41151807

Biostar Pharmaceuticals's return on assets of this year was 0.02305284. Biostar Pharmaceuticals's return on assets of last year was -0.41151807. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biostar Pharmaceuticals's current Net Income (TTM) was 0.94. Biostar Pharmaceuticals's current Cash Flow from Operations (TTM) was 8.59. ==> 8.59 > 0.94 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep17)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep16 to Sep17
=0/41.3516
=0

Gearing (Last Year: Sep16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep15 to Sep16
=0/52.5644
=0

Biostar Pharmaceuticals's gearing of this year was 0. Biostar Pharmaceuticals's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep17)=Total Current Assets/Total Current Liabilities
=0.997/5.279
=0.18886153

Current Ratio (Last Year: Sep16)=Total Current Assets/Total Current Liabilities
=7.292/6.533
=1.1161794

Biostar Pharmaceuticals's current ratio of this year was 0.18886153. Biostar Pharmaceuticals's current ratio of last year was 1.1161794. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biostar Pharmaceuticals's number of shares in issue this year was 2.637. Biostar Pharmaceuticals's number of shares in issue last year was 2.211. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.037/0.318
=-0.1163522

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.72/3.905
=0.44046095

Biostar Pharmaceuticals's gross margin of this year was -0.1163522. Biostar Pharmaceuticals's gross margin of last year was 0.44046095. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep16)
=0.318/40.559
=0.00784043

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep15)
=3.905/78.468
=0.04976551

Biostar Pharmaceuticals's asset turnover of this year was 0.00784043. Biostar Pharmaceuticals's asset turnover of last year was 0.04976551. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biostar Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Biostar Pharmaceuticals  (OTCPK:BSPM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biostar Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biostar Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biostar Pharmaceuticals (Biostar Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 588 Shiji Xi Avenue, Shaanxi Province, Xianyang, CHN, 712046
Biostar Pharmaceuticals Inc through its subsidiaries involves in the development, manufacturing, and marketing of pharmaceutical products for a variety of diseases and conditions in the People's Republic of China where it generates most of its revenues. The company's products include Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (OTC) medicine for chronic hepatitis B. The current product line of the company also includes several other OTC products and approximately 15 prescription-based pharmaceuticals. Its products are derived from medicinal herbs that are either grown at its own facility or purchased from the suppliers.

Biostar Pharmaceuticals (Biostar Pharmaceuticals) Headlines